de la Cruz-Merino L - Search Results

1

[An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate].

Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-Merino L, Álvaro Naranjo T. Noguera R, et al. Rev Esp Patol. 2019 Apr-Jun;52(2):92-102. doi: 10.1016/j.patol.2018.11.003. Epub 2019 Feb 10. Rev Esp Patol. 2019. PMID: 30902384 Review. Spanish.

2

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H. Dummer R, et al. Lancet Oncol. 2023 Dec;24(12):e461-e471. doi: 10.1016/S1470-2045(23)00334-0. Epub 2023 Jul 14. Lancet Oncol. 2023. PMID: 37459873

3

Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization.

Jiménez-Cortegana C, Salamanca E, Palazón-Carrión N, Sánchez-Jiménez F, Pérez-Pérez A, Vilariño-García T, Fuentes S, Martín S, Jiménez M, Galván R, Rodríguez-Chacón C, Sánchez-Mora C, Moreno-Mellado E, Gutiérrez-Gutiérrez B, Álvarez N, Sosa A, Garnacho-Montero J, de la Cruz-Merino L, Rodríguez-Baño J, Sánchez-Margalet V. Jiménez-Cortegana C, et al. Among authors: de la cruz merino l. Front Immunol. 2023 Nov 14;14:1266659. doi: 10.3389/fimmu.2023.1266659. eCollection 2023. Front Immunol. 2023. PMID: 38035104 Free PMC article.

4

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA, Weber J. Larkin J, et al. Clin Cancer Res. 2023 Sep 1;29(17):3352-3361. doi: 10.1158/1078-0432.CCR-22-3145. Clin Cancer Res. 2023. PMID: 37058595 Free PMC article.

5

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations.

Vázquez-Montero L, de la Gala MDCÁ, de la Cruz-Merino L. Vázquez-Montero L, et al. Front Oncol. 2023 Jun 19;13:1187840. doi: 10.3389/fonc.2023.1187840. eCollection 2023. Front Oncol. 2023. PMID: 37404764 Free PMC article. Review.

6

[2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary].

Matías-Guiu X, Fusté V, Iglesias L, Balañá C, Concha Á, de la Cruz-Merino L, Nieto B, Pané M, Sanz J, Losa F. Matías-Guiu X, et al. Rev Esp Patol. 2019 Jan-Mar;52(1):33-44. doi: 10.1016/j.patol.2018.08.002. Epub 2018 Oct 10. Rev Esp Patol. 2019. PMID: 30583830 Review. Spanish.

7

[An integral view of cancer (II). Fields of investigation and emerging biomarkers].

Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-Merino L, Álvaro Naranjo T. Noguera R, et al. Rev Esp Patol. 2019 Oct-Dec;52(4):222-233. doi: 10.1016/j.patol.2019.04.005. Epub 2019 Jun 11. Rev Esp Patol. 2019. PMID: 31530405 Review. Spanish.

8

[An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies].

Noguera R, Burgos-Panadero R, Lucantoni F, de la Cruz-Merino L, Álvaro Naranjo T. Noguera R, et al. Rev Esp Patol. 2020 Apr-Jun;53(2):88-99. doi: 10.1016/j.patol.2019.08.001. Epub 2019 Nov 22. Rev Esp Patol. 2020. PMID: 32199599 Review. Spanish.

9

Integrating the Tumor Microenvironment into Cancer Therapy.

Sanegre S, Lucantoni F, Burgos-Panadero R, de La Cruz-Merino L, Noguera R, Álvaro Naranjo T. Sanegre S, et al. Cancers (Basel). 2020 Jun 24;12(6):1677. doi: 10.3390/cancers12061677. Cancers (Basel). 2020. PMID: 32599891 Free PMC article. Review.

10

Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.

Monferrer E, Vieco-Martí I, López-Carrasco A, Fariñas F, Abanades S, de la Cruz-Merino L, Noguera R, Álvaro Naranjo T. Monferrer E, et al. Metabolites. 2021 Apr 23;11(5):264. doi: 10.3390/metabo11050264. Metabolites. 2021. PMID: 33922558 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page